Rifampicin and ethambutol in retreatment of chronic pulmonary tuberculosis.
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000139:chemically induced; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D011859:Radiography; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D004977:Ethambutol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D012293:Rifampin